Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving imatinib mesylate together with decitabine
works in treating patients with accelerated or blast phase chronic myelogenous leukemia.
Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for
cancer cell growth. Drugs used in chemotherapy use different ways to stop cancer cells from
dividing so they stop growing or die. Giving imatinib mesylate together with decitabine may
kill more cancer cells